At ASAC PHARMACEUTICAL IMMUNOLOGY we have been working in the field of allergen and bacterial immunotherapy since 1986.

Our production and commercial activity has developed steadily at our plant in Alicante, offering services to Spain, Latin America, various European countries and the Middle East. Furthermore, for some time our group has been carrying out important work in Brazil and Mexico at our international subsidiaries, IPI ASAC do Brazil and IPI ASAC Mexico.

We have two production sites, one in Alicante (Spain) and another in Sao Paulo (Brazil). A wide range of products are manufactured at these plants, such as skin prick tests (allergy diagnosis), allergen immunotherapy vaccines, bacterial vaccines, autovaccines and allergenic and bacterial bulk. At the Alicante plant we carry out an important activity of manufacturing individualised sublingual vaccines.

1995

IPI Brazil

2005

STALLERGENES
deal
Sale of IPI Brand

Change of the company name
from IPI to API

2017

Remodelling
facilities

2020

We continue to innovate and launch new sublingual hyposensitising allergen vaccines with increased therapeutic concentration.

1986

Founded in 1986
Alacan IPI Division

2000

IPI Mexico

2013

Increased coverage in Latin America

2019

Manufacturing activity resumes

1986

Founded in 1986
Alacan IPI Division

1995

IPI Brazil

2000

IPI Mexico

2005

STALLERGENES
deal
Sale of IPI Brand
Change of the company name
from IPI to API

2013

Increased coverage in Latin America

2017

Remodelling
facilities

2019

Manufacturing activity resumes

2020

We continue to innovate and launch new sublingual hyposensitising allergen vaccines with increased therapeutic concentration

As the patient is our priority, all our products are based on two pillars:

Safety

Efficacy

OUR PHILOSOPHY

An investment in knowledge always pays the best interest
Benjamin Franklin

SAFETY AND EFFICACY

For us, the priority is the patient. We want to help people with our products, both therapeutically and preventively. All our products are based on two pillars: safety and efficacy

EXCELLENCE AND QUALITY

Following a high level of excellence and quality of our products and processes, our aim is to become a national and international reference. Furthermore, we aim to be leaders in order to be recognised as an excellent company in which to work and invest.

SUSTAINABILITY, INNOVATION AND RESEARCH

We have created a sustainable business that provides innovative solutions. Our business strategy is based on increasing innovation in R&D and in-house and third-party manufacturing of vaccines. We contribute significantly to research and development, making treatments increasingly targeted and effective.

INTERNATIONAL EXPANSION

Expansion EN Placeholder
Expansion EN
Menu